|
|
|
|
 Dr Nicolò Manaresi,
Chief Technology Officer Silicon Biosystems As co-founder of Silicon Biosystems, Dr. Manaresi served as its president and CEO through the early stages of the company. Prior to the founding of Silicon Biosystems, Dr. Manaresi was a research fellow at the University of Bologna and a long-time consultant to STMicroelectronics in the field of innovative sensors based on microelectronic technologies.
Dr. Manaresi holds a Degree and Ph.D. in Electrical Engineering and Computer Sciences from the University of Bologna, Italy, in 1993 and 1999, respectively.
In 1996 he spent one year as a Research Assistant at the Swiss Federal Institute of Technology, Zurich, Switzerland.
Co-author of more than 40 scientific papers, one of which, A CMOS Chip for Individual Cell Manipulation and Detection, received the IEEE 2003 International Solid Circuit Conference Jan Van Vessem Award for outstanding European papers .
Dr. Manaresi is co-inventor of more than 20 European and US Patents.
Appearing: DAY 2 WEDNESDAY 22 SEPTEMBER – IMPROVING PRE-CLINICAL & EARLY DEVELOPMENT 3.10pm The DEPArray™ System: enabling the molecular characterization of circulating tumor cells to bridge the gap between prognosis and personalized therapy
- CTC count is a valuable tool for prognostic indication. However the full potential of CTC in personalised therapy and translational research is bound to their molecular profiling.
- Enrichment of techniques currently available provide a level of purity incompatible with the majority of molecular analyses.
- The DEPArray™ System using image-based single-cell sorting from small cell loads is designed to deliver 100% pure cells which, following whole genome amplification, may provide the key to the unravelling of their molecular profile.
Dr Nicolò Manaresi, Chief Technology Officer,
Silicon Biosystems 4.40pm Expert Q&A panel discussion: are we aiming at a moving target?
- Different approaches to targeted therapy: is the target actually the driving force?
- What are the implications for therapies which have an effect in patients without a particular target? Does this interrupt that targeted cancer therapy paradigm?
- Understanding strategies and solutions to improve targets for cancer therapy.
Senior Vice President Oncology,
Merck Serono Head of Experimental Oncology Department,
Institute de Recherche Pierre Fabre Dr Nicolò Manaresi, Chief Technology Officer,
Silicon Biosystems Senior Group Leader,
Friedrich Miescher Institute for Biomedical Research (Part of the Novartis Research Foundation) |
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
|
|
|
|
|
|
